Daily pill can double survival time for world’s deadliest cancer, trial shows
A trial of 500 patients found daraxonrasib roughly doubled survival in advanced pancreatic cancer, with fewer side effects than chemotherapy.
Intelligence analysis by GPT-5.4 Mini
Researchers presented early results for daraxonrasib, a daily pill aimed at the Kras pathway that drives most pancreatic cancers. In patients whose cancer had spread, it extended average survival from about 6.6-6.7 months to 13.2 months.
Pancreatic cancer is a very hard cancer to treat, like a fire that starts deep inside a wall where it is hard to reach. This new pill, daraxonrasib, is meant to turn off one of the main switches that helps the cancer grow.
In the study, people taking the pill lived longer than people getting regular cancer drugs. The pill also seemed to cause fewer bad side effects, which matters because treatment should not make life harder than it already is.
Doctors are excited because this could be a big step forward after many years with few good options. It is not a cure, but it could give people more time with their families.
Analysis
What the trial found
A clinical trial of 500 patients with advanced pancreatic cancer found that daraxonrasib, taken as a daily pill, was linked to much longer survival than chemotherapy. The average survival in the trial was 13.2 months for patients on the drug, compared with 6.6 to 6.7 months for those receiving chemotherapy. The trial also reported fewer side effects.
Why this matters
Pancreatic cancer is described in the article as the world’s deadliest cancer, in part because it is often found late and has very few effective treatments. More than half of patients are diagnosed only after the disease has already spread, which limits treatment options and makes survival especially poor.
How the drug works
Daraxonrasib targets Kras, a protein that helps drive nearly all pancreatic cancers. The article says more than 90% of patients with the most common form, pancreatic ductal adenocarcinoma, have a Kras mutation. The drug belongs to a newer class of Ras inhibitors and is designed to switch off the cancer signal even across different Kras variants. That matters because Kras has long been viewed as a difficult target, and researchers quoted in the story called the result a major step forward.
What comes next
The findings were presented at the American Society of Clinical Oncology meeting in Chicago. Experts quoted in the article said the result could mark a treatment breakthrough, but they also stressed the practical next step: getting these kinds of drugs to patients. The article also notes that similar approaches are being tested in other cancers, including lung and colon cancer.
Key points
- A trial of 500 patients with advanced pancreatic cancer found daraxonrasib doubled average survival versus chemotherapy.
- Patients on the drug lived about 13.2 months on average, compared with 6.6 to 6.7 months for chemotherapy.
- The article says the pill had fewer side effects than chemotherapy.
- Experts at the ASCO meeting called the result a major breakthrough or “gamechanger.”
- The drug targets Kras, a mutation seen in most pancreatic ductal adenocarcinomas.
